Back to All Blog Posts
30.04.2026

Co-creating Patient Experience Data: Insights from Non-Dystrophic Myotonia (NDM) and Myotonic Dystrophy (DM) Collaboration

Highlights Count-Down to 10 Years admedicum in June 2026 Nr. 3

Why Patient Experience Data are so important

Patient experience data (PXD) has become a cornerstone of meaningful patient engagement. Co-creation of such data, carried out jointly by patient experts, industry teams, and facilitation partners, ensures that evidence reflects the real lived experience of those affected, particularly in rare diseases where traditional clinical datasets are inherently limited. Health systems increasingly rely on patient-generated insights to guide regulatory, clinical, and access decisions.  This is where structured collaboration becomes essential to producing credible, high-impact outcomes.

Understanding Non-Dystrophic Myotonia (NDM) and Myotonic Dystrophy (DM) Through Co‑Created Evidence (2017–today)

Since 2017, admedicum has collaborated with Lupin Neurosciences and patient advocates across Europe, the UK, and the United States, to co-create high‑quality patient experience data on NDM and DM. This collaboration involved people living with NDM and DM, caregivers, clinical experts, patient organisations, and Lupin’s Medical Affairs team, all working together to map disease burden, support treatment access, and document unmet needs in systematic, internationally coordinated projects. Patient experience data, suitable for clinician and regulatory use, were peer‑reviewed and presented at international conferences.

The partnership resulted in several landmark outputs: First and foremost, The European patient survey was an important component for supporting the EMA’s decision to maintain the orphan-drug-status of Mexiletine for NDM in November 2018. Following that starting point, further outputs resulted in a burden‑of‑disease survey, a multi‑country study on treatment access barriers, and an international patient‑reported survey on the impact of myotonia in DM. These studies, co‑created with patient representatives from the earliest design steps through dissemination, have contributed to the advancement of global understanding of NDM and DM.

Perspectives from the Collaborators

No items found.

Exemplifying State-Of-The-Art Patient Experience Data Collection

Scientific poster titled "The Impact of non-dystrophic Myotonia on PAtients and Caregivers' qualiTy of life (IMPACT) survey results

Across all publications, the collaboration followed a consistent patient‑engagement logic: early involvement, equal‑footed contribution, methodological transparency, and continuous dialogue. The collaboration ensured that patient representatives were not merely consulted but meaningfully involved in shaping research questions, reviewing survey tools, interpreting results, and validating the narrative used in external communications.

Together, these projects demonstrate how co‑created patient experience data can shape understanding, guide responsible development, and elevate the patient voice within the neuromuscular field. They also illustrate the power of long‑term, trust‑based collaboration between industry, patient organisations, and a neutral facilitating partner.

Why We Do What We Do At admedicum

This approach reflects admedicum’s core mission: enabling structured co‑creation between patient communities and life‑science partners to generate insights that are both scientifically robust and directly relevant to people’s daily lives. We feel honored and proud to being part of this strong collaboration!